Pavmed Inc (PAVM)

Jan 16, 2025

PAVmed shareholders approve stock issuance and charter amendment - Investing.com India

Jan 16, 2025

Jan 13, 2025

Lucid Diagnostics Achieves Record-Breaking Quarter with 84% Surge in EsoGuard DNA Test Volume - StockTitan

Jan 13, 2025

Jan 10, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 10, 2025

Jan 08, 2025

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - Kilgore News Herald

Jan 08, 2025

Dec 26, 2024

Lucid Inks New Partnership With VITALExam: Stock to Gain? - MSN

Dec 26, 2024

Dec 25, 2024

Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophag - GuruFocus.com

Dec 25, 2024

Dec 23, 2024

Lucid Gains Extension of Compliance by NASDAQ - Baystreet.ca

Dec 23, 2024

Dec 23, 2024

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - Marketscreener.com

Dec 23, 2024

Dec 23, 2024

Lucid Diagnostics Gets Nasdaq Extension to Meet $1 Listing Requirement Through June 2025 - StockTitan

Dec 23, 2024

Dec 20, 2024

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Eastern Progress Online

Dec 20, 2024

Dec 19, 2024

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - GuruFocus.com

Dec 19, 2024

Dec 19, 2024

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - The Eastern Progress Online

Dec 19, 2024

Dec 19, 2024

PAVmed stock plunges to 52-week low, touches $0.6 By Investing.com - Investing.com Canada

Dec 19, 2024

Dec 18, 2024

PAVmed stock plunges to 52-week low, touches $0.6 - Investing.com

Dec 18, 2024

Dec 17, 2024

Critical Survey: PAVmed (NASDAQ:PAVM) and PolyPid (NASDAQ:PYPD) - Defense World

Dec 17, 2024

Dec 14, 2024

PAVmed (NASDAQ:PAVM) versus Embecta (NASDAQ:EMBC) Financial Review - Defense World

Dec 14, 2024

Dec 11, 2024

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuar - GuruFocus.com

Dec 11, 2024

Dec 11, 2024

Lucid Diagnostics' EsoGuard Shows Breakthrough 85% Compliance Rate in Major Clinical Study - StockTitan

Dec 11, 2024

Dec 11, 2024

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire) - Aktiellt

Dec 11, 2024

Dec 11, 2024

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - PR Newswire

Dec 11, 2024

Dec 10, 2024

PAVmed (NASDAQ:PAVM) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World

Dec 10, 2024

Dec 07, 2024

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - The Eastern Progress Online

Dec 07, 2024

Dec 03, 2024

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones - Lelezard

Dec 03, 2024

Dec 03, 2024

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones – Company AnnouncementFT.com - Financial Times

Dec 03, 2024

Dec 03, 2024

Lucid Diagnostics Secures $21.95M Convertible Note Financing, Extends Cash Runway - StockTitan

Dec 03, 2024

Dec 02, 2024

Symbol Lookup - GuruFocus.com

Dec 02, 2024

Nov 23, 2024

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Vi - GuruFocus.com

Nov 23, 2024

Nov 23, 2024

PAVmed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 23, 2024

Nov 21, 2024

Lucid Diagnostics Provides Business Update and Third Quarter 202 - GuruFocus.com

Nov 21, 2024

Nov 20, 2024

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - PR Newswire

Nov 20, 2024

Nov 20, 2024

PAVmed Q3 2024 Earnings Preview - MSN

Nov 20, 2024

Nov 20, 2024

Lucid Diagnostics Seeks Medicare Coverage for EsoGuard Test with New Clinical Data - StockTitan

Nov 20, 2024

Nov 18, 2024

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, D - GuruFocus.com

Nov 18, 2024

Nov 17, 2024

PAVmed Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan

Nov 15, 2024

Nov 15, 2024

Earnings call: PAVmed reports strategic shifts and Q3 financials - Investing.com

Nov 15, 2024

Nov 15, 2024

PAVmed Inc. (NASDAQ:PAVM) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Nov 15, 2024

PAVmed Inc. (PAVM) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 15, 2024

PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring - Yahoo Finance

Nov 15, 2024

Nov 15, 2024

PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Reven - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring By GuruFocus - Investing.com Canada

Nov 15, 2024

Nov 14, 2024

First Manhattan Co. LLC's Strategic Acquisition of PAVmed Inc Sh - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

PAVmed Inc Reports Q3 2024 Earnings: Revenue at $996,000, Non-GA - GuruFocus.com

Nov 14, 2024

Nov 14, 2024

PAVmed Reports Record Revenue and Strategic Restructuring - TipRanks

Nov 14, 2024

Nov 14, 2024

PAVmed Provides Business Update and Third Quarter 2024 Financial Results - PR Newswire

Nov 14, 2024

Nov 14, 2024

PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - Kilgore News Herald

Nov 14, 2024

Nov 13, 2024

PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan

Nov 13, 2024

Nov 13, 2024

Lucid Diagnostics' EsoGuard Revenue Surges 50% YoY, Sets Record Testing Volume in Q3 | PAVM Stock News - StockTitan

Nov 13, 2024

Nov 13, 2024

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results - PR Newswire

Nov 13, 2024

Nov 12, 2024

PAVmed's Earnings: A Preview - Benzinga

Nov 12, 2024

Nov 07, 2024

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication – Company AnnouncementFT.com - Financial Times

Nov 07, 2024

Nov 07, 2024

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - PR Newswire

Nov 07, 2024

Nov 06, 2024

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers - BioSpace

Nov 06, 2024

Nov 05, 2024

Lucid Diagnostics expands direct contracting for cancer testing - Investing.com

Nov 05, 2024